Dawn Muhlestein, PA
Surgical · Bountiful, UTNPI 1629374582
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.2% of the total across 70 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 19.8% — the pattern of someone who eats at a lot of different presentations.
Across 70 payments — averaging $24.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- 180 Medical, Inc.$338
- Boston Scientific$167
- AbbVie$158
- Astellas Pharma US Inc$133
- Teleflex LLC$105
- Rochester Medical Corporation$95
- plus $711 from 20 others
What the payments were for
- Food & beverage$1,64396%
- Education$654%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| 180 Medical, Inc. | 10 | $338 |
| Boston Scientific | 4 | $167 |
| AbbVie | 9 | $158 |
| Astellas Pharma US Inc | 6 | $133 |
| Teleflex LLC | 5 | $105 |
| Rochester Medical Corporation | 4 | $95 |
| Sumitomo Pharma America, Inc. | 4 | $92 |
| Convatec Inc. | 3 | $85 |
| Coloplast | 3 | $59 |
| Urovant Sciences Inc | 2 | $44 |
| Procept Biorobotics Corporation | 2 | $43 |
| Myriad Genetic Laboratories, Inc. | 1 | $41 |
| Nevro Corp. | 2 | $38 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $37 |
| Inspire Medical Systems, Inc. | 1 | $34 |
| Olympus America Inc. | 2 | $29 |
| Urogen Pharma, Inc. | 1 | $29 |
| Dendreon Pharmaceuticals LLC | 1 | $27 |
| Dentsply IH AB | 1 | $27 |
| Valencia Technologies Corporation | 1 | $22 |
| Ferring Pharmaceuticals Inc. | 1 | $22 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Arbor Pharmaceuticals, Inc. | 1 | $18 |
| ABC Home Medical Supply, Inc. | 1 | $18 |
| Medtronic | 1 | $15 |
| Biodelivery Sciences International, Inc. | 1 | $13 |
How this compares
$1,708 in reported general payments places this provider in the 80th percentile of 121 surgical providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 189 | $148,530 |
| GemtesaVibegron | 55 | $55,016 |
| Mirabegron ErMirabegron | 19 | $11,382 |
| Solifenacin Succinate | 234 | $9,144 |
| Methenamine Hippurate | 245 | $7,241 |
| Trospium Chloride ErTrospium Chloride | 39 | $6,765 |
| Estradiol | 97 | $6,054 |
| Trospium Chloride | 107 | $5,612 |
| Trimethoprim | 57 | $5,492 |
| CefuroximeCefuroxime Axetil | 183 | $2,526 |
| Tamsulosin Hcl | 143 | $1,982 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 52 | $1,505 |
| Cefdinir | 63 | $1,217 |
| Doxycycline Monohydrate | 45 | $865 |
| Doxycycline Hyclate | 37 | $591 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $133 | $148,530189 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $92 | $55,01655 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 121 surgical providers in Utah.
Other surgical in Bountiful
- Scott HadfieldSalt Lake City$10K
- Brittany CrossSalt Lake City$6K
- Jason HoldenDraper$6K
- Stephen LoperAmerican Fork$5K
- Drew LambourneProvo$4K
- Brittney TaylorSalt Lake City$4K
- Richard ClowardOgden$4K
- David TranterDraper$3K
- Bradley BurtonAmerican Fork$3K
- Lindsay AdamsAmerican Fork$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.